13G Filing: Viking Global and aTyr Pharma Inc (LIFE)

Page 12 of 14

Page 12 of 14 – SEC Filing

Schedule 13G PAGE 12 of 14

CUSIP No. 002120103

E. O. Andreas Halvorsen, David C. Ott and Rose S. Shabet
(a) Amount beneficially owned: 2,932,229
(b) Percent of class: 9.5%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
2,932,229
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 2,932,229

Mr. Halvorsen, Mr. Ott and Ms. Shabet, as
Executive Committee Members of Viking Global Partners LLC (“VGPL”),
general partner of VGI and Opportunities GP,
have shared authority to dispose of and vote the shares of
Common Stock beneficially owned by VGI and Opportunities GP.
None of Mr. Halvorsen, Mr. Ott and Ms. Shabet directly
owns any shares of Common Stock.

Based on Rule 13d-3 of the Act, each may be deemed to beneficially
own the shares of Common Stock directly held by Opportunities Fund.

Mr. Halvorsen, Mr. Ott and Ms. Shabet each beneficially own
2,932,229 shares of Common Stock consisting of (i) 1,777,784 shares
of Common Stock directly and beneficially owned by Opportunities Fund
and (ii) 1,154,445 shares of Common Stock underlying the Preferred Stock
directly and beneficially owned by Opportunities Fund.

Excluded from each Reporting Person’s beneficial ownership are
(i) 10,275,315 shares of Common Stock issuable upon the conversion of shares
of Preferred Stock directly owned by Opportunities Fund and
(ii) 4,952,829 shares of Common Stock issuable upon the exercise of warrants
directly owned by Opportunities Fund due to a conversion cap that precludes
Opportunities Fund from converting shares of Preferred Stock and
exercising such warrants to the extent that Opportunities Fund would,
after such conversion or exercise, beneficially own (as determined
in accordance with Section 13(d) of the Act) in excess of 9.5% of the shares
of Common Stock outstanding (the “Beneficial Ownership Limitation”).

The percentage of the class of Common Stock beneficially owned by each
Reporting Person is calculated based upon (i) 23,839,007 shares of Common Stock
issued and outstanding as of August 4, 2017, as reported the Issuer in its
quarterly report on Form 10-Q filed with the Securities and Exchange Commission
(the “Commission”) on August 14, 2017, (ii) 5,872,120 shares of Common Stock
issued by the Issuer on or about August 31, 2017, as reported by the Issuer
in its current report on Form 8-K filed with the Commission on August 28, 2017
and (iii) the 1,154,445 shares of Common Stock underlying shares of
Preferred Stock that could be converted by Opportunities Fund without
violating the Beneficial Ownership Limitation.

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
If this statement is being filed to report the fact that as of the
date hereof the Reporting Persons has ceased to be the beneficial
owner of more than five percent of the class of securities,
check the following.[]

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Yes, see Item 4.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
Not applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not applicable.

ITEM 10. CERTIFICATION. (if filing pursuant to Rule 13d-1(c))
By signing below each Reporting Person certifies that, to the best
of its knowledge and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the effect of
changing or influencing the control of the issuer of the securities
and were not acquired and not held in connection with or as a
participant in any transaction having that purpose or effect.

Follow Atyr Pharma Inc (NASDAQ:ATYR)

Page 12 of 14